Bristol Myers Squibb reports dip in net income for Q2 2024
Pharmaceutical Technology
JULY 29, 2024
Bristol Myers Squibb (BMS) has posted net income attributable to the company of $1.7bn during Q2 2024, a 19% drop versus $2.1bn in Q2 2023.
Mon.Jul 29, 2024
244 
Blue Light From Your Phone Really Can Affect Your Skin. Here’s How.
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 29, 2024
Social media is full of claims that everyday habits can harm your skin. It’s also full of recommendations or advertisements for products that can protect you. Now social media has blue light from our devices in its sights. So can scrolling on our phones really damage your skin? And will applying creams or lotions help?
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AAIC 2024: the evolution of Alzheimer’s clinical trials
Pharmaceutical Technology
JULY 29, 2024
Clinical trial trends point to studying combination therapies and lifestyle changes using alternate designs in Alzheimer’s research.
GSK leans on Flagship for help finding new drugs, vaccines
Bio Pharma Dive
JULY 29, 2024
The deal resembles recent Flagship alliances with Pfizer and Novo Nordisk, allowing the British pharma to comb through the company creator’s portfolio to unearth up to 10 therapies.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA approves Luye Pharma’s ERZOFRI for schizophrenia
Pharmaceutical Technology
JULY 29, 2024
The US FDA has granted approval for Luye Pharma’s ERZOFRI extended-release injectable suspension for schizophrenia in adults.
Ventyx’s TYK2 drug suffers second setback
Bio Pharma Dive
JULY 29, 2024
The company claimed “higher than anticipated” scores from trial volunteers on placebo led to the disappointing data, prompting it to halt internal trials.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
How a Mubadala partner views investing in biotech’s new normal
Bio Pharma Dive
JULY 29, 2024
Ayman AlAbdallah spoke with PharmaVoice about some of the inroads the sector has made towards a recovery and the traits he looks for in a startup.
CDMOs: Shaping The Future of Pharmaceutical Innovation
Pharma Mirror
JULY 29, 2024
The pharmaceutical industry is constantly shifting, as consumers seek the best treatments. As the market demands new solutions, drugmakers are tasked with investing heavily in research, development, manufacturing and commercialization. Meeting the needs of the sector can be challenging, especially for companies that don’t have the necessary resources.
ICMR invites expressions of interest to establish collaborating centres of excellence
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 29, 2024
The Indian Council of Medical Research (ICMR), the premier institution for biomedical research in India, has announced a request for Expressions of Interest (EoI) for the establishment of ICMR Collaborating Centres of Excellence (ICMR-CCoE) for the year 2024.
Boehringer adds to cancer drug pipeline with deal for startup Nerio
Bio Pharma Dive
JULY 29, 2024
The pharma company will pay up to $1.3 billion to acquire San Diego-based Nerio and its research into novel immune checkpoint inhibitors.
New AI model boosts early osteoporosis diagnosis for ageing populations
Pharmaceutical Technology
JULY 29, 2024
Osteoporosis is the most common metabolic bone disorder worldwide and is the leading cause of fragility fractures.
NewAmsterdam heart drug hits trial goal, but data disappoint investors
Bio Pharma Dive
JULY 29, 2024
The study is the latest test of a class of cholesterol medicines known as CETP inhibitors, which were abandoned by several large drugmakers last decade.
EC approves measure to produce radioisotopes for cancer
Pharmaceutical Technology
JULY 29, 2024
The European Commission (EC) has granted approval to a €2bn Dutch measure to produce medical radioisotopes used in cancer treatment.
Alpha Cognition's delayed-release Alzheimer's drug Zunveyl passes muster with FDA
Fierce Pharma
JULY 29, 2024
Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition. | Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Leqembi
Pharmaceutical Technology
JULY 29, 2024
The European agency said that Leqembi’s efficacy was “not large enough” to outweigh its safety risks.
AstraZeneca trumpets new Calquence combos in CLL. Can they change clinical practice?
Fierce Pharma
JULY 29, 2024
With a phase 3 trial win claimed by AstraZeneca, the heated BTK inhibitor race might see its first triplet regimen in chronic lymphocytic leukemia (CLL). | With a phase 3 win claimed by AstraZeneca, the heated BTK inhibitor race might see its first triplet regimen in chronic lymphocytic leukemia.
CHMP backs Boehringer’s Spevigo for preventing rare psoriasis flare-ups
Pharmaceutical Technology
JULY 29, 2024
The CHMP recommendation is based on positive results from the Phase IIb EFFISAYIL 2 trial which enrolled 123 patients.
UK partnership aims to support NHS use of depression app
pharmaphorum
JULY 29, 2024
Otsuka has teamed up with one of the innovation arms of the NHS to explore how a digital therapeutic (DTx) for major depressive disorder (MDD) could be deployed within the health service.The alliance with Health Innovation Oxford & Thames Valley (Oxford HIN) is focusing on Care for MDD, an app-based DTx that has been co-developed by Otsuka and digital health specialist Click Therapeutics.
CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma
Pharmaceutical Technology
JULY 29, 2024
The EMA CHMP has recommended approving MSD’s KEYTRUDA regimen as a first-line treatment for urothelial carcinoma.
Rainwater Foundation, CurePSP, Aging Mind Foundation fund innovative tauopathy research
Outsourcing Pharma
JULY 29, 2024
The Rainwater Charitable Foundation (RCF), in collaboration with CurePSP and the Aging Mind Foundation (AMF), has announced the allocation of $2 million in grants to support groundbreaking research in primary tauopathies.
With multi-state agreement worth $86M, Indivior moves to resolve more opioid litigation
Fierce Pharma
JULY 29, 2024
Suboxone maker Indivior has spent years dealing with allegations related to its role in the United States opioid epidemic, inking several settlements over that span and even witnessing its former C | More than a dozen states linked up on the agreement after accusing Indivior of fueling the opioid epidemic with its opioid addiction treatment Suboxone.
Biologics contract manufacturing: A comprehensive guide for pharmaceutical companies
pharmaphorum
JULY 29, 2024
This comprehensive guide provides pharmaceutical companies with valuable insights into biologics contract manufacturing, including the role of CDMOs and key considerations for successful partnerships.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
After tense standoff, AstraZeneca and Daiichi's Enhertu turned away by NICE on pricing grounds
Fierce Pharma
JULY 29, 2024
After a prior skirmish over tax policy in England, AstraZeneca is now butting heads with | After a prior skirmish over tax policy in England, AstraZeneca is now butting heads with officials in the country over innovative drug access.
Bridging Gaps in Rare Disease Clinical Trials: Insights from Collaborative Success in Pompe Disease Research
XTalks
JULY 29, 2024
According to the National Institutes of Health (NIH), over 7,000 identified rare diseases affect an estimated 300 million people worldwide. In fact, the non-profit organization RareX released a report titled The Power of Being Counted in June 2022 that currently identifies the number of recognized rare diseases at 10,867. Despite their individual rarity, the cumulative impact of rare diseases is staggering, with approximately one in 20 people affected by a rare condition at some point in their l
NewAmsterdam obicetrapib data disappoints some investors
pharmaphorum
JULY 29, 2024
Shares in NewAmsterdam Pharma were sliding today after it reported a phase 3 trial of obicetrapib that met its primary objective but didn't meet the expectations of some analysts and investors.The BROOKLYN study compared the oral CETP inhibitor to a placebo given on top of maximum tolerated doses of other lipid-modifying therapies, like statins and ezetimibe, in patients with heterozygous familial hypercholesterolaemia (HeFH), a genetic condition that raises blood cholesterol and the risk of hea
Study finds 3D-printed blood vessels could improve heart bypass outcomes
Pharma Times
JULY 29, 2024
Coronary heart disease is the most common form of heart and circulatory disease
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
GSK joins Flagship's flotilla of pharma partners
pharmaphorum
JULY 29, 2024
Flagship Pioneering signs another strategic-level deal with a big pharma group, with GSK agreeing an alliance potentially worth more than $7 billion
Does Frequency of a Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-Like Illness Vary Between Those with Differing COVID Test Results?
Pharmaceutical Commerce
JULY 29, 2024
A cohort study investigates whether or not the prevalence of these types of illnesses can vary among individuals who are COVID-positive versus negative.
Ipsen's Alagille drug backed by CHMP again, with new name
pharmaphorum
JULY 29, 2024
Ipsen gets CHMP backing for Alagille syndrome therapy odevixibat, with a new brand name that it hopes will unlock orphan status in the EU
Interview: Phastar's Graham Clark on how AI and data are really shaping the pharma landscape
Outsourcing Pharma
JULY 29, 2024
In an insightful interview, Clark delves into the transformative landscape of clinical trials and the pivotal role data and AI play in this evolution.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content